BACKGROUND: Supraventricular tachycardia is common after heart transplantation. Adenosine, the standard therapy for treating supraventricular tachycardia in children and adults without transplantation, is relatively contraindicated after transplantation because of a presumed risk of prolonged atrioventricular block in denervated hearts. This study tested whether adenosine caused prolonged asystole after transplantation and if it was effective in blocking atrioventricular nodal conduction in these patients.
S upraventricular tachycardia (SVT) can affect up to 50% of children and adults after heart transplantation, compromising cardiac output and prompting investigation for acute organ rejection. [1] [2] [3] [4] The current standard for acute SVT management for patients without transplanted hearts is adenosine, an endogenous nucleoside. [5] [6] [7] Adenosine causes atrioventricular block by altering the atrioventricular node action potential; aiding in the diagnosis of atrial flutter, fibrillation, and tachycardia; and treating atrioventricular and atrioventricular nodal reentrant tachycardias. 5, 8, 9 Adenosine has been considered relatively contraindicated in heart transplant recipients because of postoperative parasympathetic denervation, which increases the sensitivity of the sinus and atrioventricular node receptors. [10] [11] [12] Concerns remain about the potential for prolonged atrioventricular block after case reports in the 1990s described bradycardia following adenosine administration. 13, 14 However, the safety and efficacy of adenosine have never been formally assessed in the heart transplantation population.
The primary aim of this study was to assess the safety and efficacy of adenosine to block the atrioventricular node in healthy pediatric and young adult heart transplantation patients to evaluate adenosine as firstline therapy in this population.
METHODS Study Design
A single-center prospective clinical study was conducted that included pediatric and young adult heart transplantation patients (age, 6 months-25 years) who presented for routine cardiac catheterization and biopsy at New York Presbyterian/ Morgan Stanley Children's Hospital, Columbia University Medical Center during the study period from July 2015 until April 2016. Patients underwent initial screen by chart review and were then recruited via telephone and during transplantation clinic visits. Patients unable to provide informed consent in English were excluded.
After screening, patients were excluded if they were undergoing treatment for cellular or antibody-mediated rejection, were on intravenous inotropic medication, were <2 weeks posttransplantation, or were known to have coronary allograft vasculopathy, conduction disease (first-, second-, or third-degree atrioventricular block, preexisting sinus node dysfunction), or systolic ventricular dysfunction (indicated by left ventricular ejection fraction <50% measured by 5/6 area×length on the most recent echocardiogram). Patients were also excluded if they had hemodynamic or coronary angiographic concern for acute rejection or coronary allograft vasculopathy at the time of catheterization. A summary of recruitment, enrollment, and testing is provided in Figure 1 .
All enrolled patients underwent catheterization of the right side of the heart (with or without catheterization of the left side of the heart and coronary angiography) followed by endomyocardial biopsy as part of routine clinical care. All subjects taking dipyridamole were instructed to stop the medication 3 days before adenosine testing because of concerns about adenosine potentiation. 15 After catheterization but before the removal of central access, a 4F quadripolar pacing catheter (St. Jude Medical, St. Paul, MN) was introduced into the right ventricle. The central sheath was then retracted from the ventricle to the vena cava. Pacing thresholds were tested, and the electric output was set at greater than twice the capture threshold. Pacing catheter placement and electrocardiographic measurements were confirmed by a pediatric electrophysiologist (E.S.S., L.L.).
Sterile preparations of intravenous adenosine (6 mg/2 mL; Sagent Pharmaceuticals, Inc, Schaumburg, IL) were rapidly administered via central access with a 3-way stopcock and saline flush. Patients <60 kg were serially dosed by weight (12.5, 25, 50 , 100, and 200 μg/kg), and patients ≥60 kg received standard escalating doses (0.8, 1.5, 3, 6, and 12 mg). Adenosine doses were given incrementally until atrioventricular block was achieved or clinically significant asystole (either a sinus pause or atrioventricular block ≥12 seconds was the predetermined criterion to initiate ventricular pacing) was encountered (Figure 2A ). To facilitate study execution, weights were rounded up to the nearest 2.5 kg if <60 kg. For patients who demonstrated sinus pauses of >2 seconds or sinus bradycardia but without atrioventricular block, the pacing catheter was retracted to the right atrium, and the same
Clinical Perspective
What Is New?
• This is the first prospective clinical study of adenosine use in pediatric and young adult patients after heart transplantation.
• It is the first study describing systematic use of adenosine at doses much lower than the recommended pediatric advanced life support and adult advanced cardiovascular life support algorithms to block atrioventricular conduction in this at-risk patient population.
• The study establishes both safe and effective starting doses (25 μg/kg; 1.5 mg for patients ≥60 kg), in addition to a stepwise therapy escalation plan to avoid prolonged bradycardia.
What Are the Clinical Implications?
• The study makes a new clinical recommendation for safe and effective adenosine use for supraventricular tachycardia, the most common arrhythmia after transplantation.
• Emergency responders, nurses, and physicians now have a clinically tested starting dose and therapy algorithm for this medication, previously considered to be dangerous in the transplantation patient with supraventricular tachycardia.
• Although patients after heart transplantation may require less adenosine to achieve atrioventricular block, it is a safe and effective first-line therapy for the evaluation and treatment of tachycardia in this population.
adenosine dose was repeated with right atrial pacing at a rate of 100 bpm. Surface electrocardiographic measurements were obtained with the EP-WorkMate recording system (St. Jude Medical) or by standard 12-lead ECG.
Measured Outcomes
Both the safety and efficacy of adenosine use in pediatric and young adult heart transplantation patients were tested. The primary outcome of interest was safety, defined as freedom from rescue ventricular pacing. It was determined a priori that a sinus pause or atrioventricular block ≥12 seconds after adenosine administration would be considered clinically significant asystole and that intracardiac pacing would be initiated and testing terminated. The secondary outcome of interest was atrioventricular block (efficacy), defined by ≥1 nonconducted P waves on ECG. In exploratory analyses, the total adenosine effect, defined as the time from initial atrioventricular block to return of consistent atrioventricular nodal conduction ( Figure 2B ), and the adenosine dose per kilogram necessary to achieve atrioventricular block were examined.
Predictors of Interest
The primary predictor of interest was adenosine dose: the maximum dose administered without inducing clinically significant asystole and the minimum dose required to achieve atrioventricular block. In secondary analyses, effects of age, sex, total organ ischemic time, time since transplantation, graft rejection history, baseline PR interval, use of general anesthesia for the catheterization, cardiac index, right ventricular end-diastolic pressure, and pulmonary capillary wedge pressures on each of the measured outcomes were assessed. Total organ ischemic time was defined as total time (minutes) from aortic crossclamp placement (during donor procurement) to removal in the recipient (during implantation). Rejection history was assessed first as a categorical variable and then as a continuous variable by measuring time from last acute rejection to date of adenosine testing.
Statistical Analysis
A sample size of 80 patients was needed to achieve 80% power to detect a proportion of intervention as low as 4%, with a margin of error of at most 6%, given a 95% confidence interval (CI). Clinical and demographic characteristics were described with the use of medians (interquartile ranges) or means (SDs) for continuous variables as appropriate. Overall and dose-specific proportions of intervention and atrioventricular block, including 95% CIs, were calculated. The mean and SD for the total adenosine effect were calculated at the maximum dose.
The effects of patient characteristics on the maximum dose per kilogram and total adenosine effect were assessed by univariable and multivariable linear regression. Variables with values of P≤0.10 were considered for multivariable models, which were then built via a forward stepwise procedure. In final models, a value of P<0.05 was considered statistically significant. For the total adenosine effect model, robust standard All cardiac transplantation (HTx) patients 6 months to 25 years of age at Morgan Stanley Children's Hospital undergoing routine cardiac catheterization (CC) from July 2015 until April 2016 were recruited. After 166 patients were screened, 135 were eligible and 80 underwent adenosine testing. *Right ventricular (RV) rescue pacing was the primary outcome. †Atrioventricular (AV) block was the secondary outcome.
errors were used, clustering by dose. Sensitivity analyses were performed for all outcomes, stratifying patients by weight category (>60 or <60 kg).
The authors had full access to all data in the study and were equally responsible for the integrity of the data, including all analyses conducted (by B.R.A. and M.E.R.) with Stata software, version 13.1 (StataCorp, College Station, TX).
Study Oversight
All study activities were approved by the Institutional Review Board at Columbia University Medical Center. Ethics consultation for the development of human subject protection strategies was obtained from the Irving Institute for Clinical and Translational Research. Written informed consent and assent were obtained in accordance with the Institutional Review Board and Common Rules 46.406 and 46.408. The clinical study was registered with the US National Institutes of Health (URL: http:www.clinicaltrials.gov. Unique identifier: NCT02462941). Safety monitoring was established on the basis of the primary end point, and statistical consideration for early termination was set at a proportion of intervention of ≥15%.
RESULTS

Patient Characteristics
A total of 166 pediatric and young adult heart transplantation patients were screened; 135 (81%) were deemed eligible ( Figure 1 ). Of the 31 ineligible patients, 17 were excluded because of language barriers, 2 for coronary allograft vasculopathy, and 2 for ongoing rejection; study contact was deferred by the primary team for 10 patients with ongoing clinical hardships. No patient was excluded for preexisting conduction disease or ventricular dysfunction. Consent was obtained from 87 of the eligible patients (64%), of whom the first 80 underwent and completed adenosine testing. Of the 48 patients without consent, 38 patients declined to participate, 9 patients had a catheterization scheduled beyond the study period end date, and 1 patient died of unrelated events.
Demographic details of the study population are listed in Table 1 . Nearly half the patients (45%) were female, with a median age of 13.6 years (range, 1.1-24.0 years). The median weight was 50.4 kg (range, 7.8-120.0 kg), and 32 patients (40%) were ≥60 kg. The most common primary indication for heart transplantation was cardiomyopathy (60%) followed by congenital heart disease (30%). The median duration from transplantation was 4.5 years (range, 25 days-19.9 years) at the time of testing. Twenty patients (25%) were <2 years from transplantation. Nearly half of the patients had a history of acute rejection and were a median of 2.3 years (interquartile range, 0.5-6.3 years) from the last episode. All patients had normal cardiac function on echocardiogram a median of 3.3 months (interquartile range, 1.6-6.0 months) Figure 2 . Adenosine testing after heart transplantation.
A,
before testing (Quantitative left ventricular ejection fraction was not evaluated for 2 patients because of poor image quality but was qualitatively deemed to be ≥50%).
Hemodynamic measurements, including mean cardiac index (calculated by Fick equation), mean right ventricular end-diastolic pressure, and pulmonary capillary wedge pressure, were within normal limits for all patients (Table 1) . Endomyocardial biopsies with International Society for Heart Transplantation grade 0 or 1A were observed in 76 patients (95%), grade 1B biopsies in 2 patients (2.5%), and biopsies insufficient for grading in 2 patients (2.5%). No patient tested positive for antibodymediated rejection by histology or immunopathology. 16 
Outcome Measures
None of the 80 patients (0%; 95% CI, 0-3) experienced clinically significant asystole requiring rescue ventricular pacing (safety) after adenosine administration (Table 2) . Atrioventricular block (efficacy) was observed in 77 patients (96%; 95% CI, 89-99). Atrioventricular block was not observed in 3 patients, even after the maximum adenosine dose. Cumulatively, 0% of patients demonstrated atrioventricular block after receiving adenosine at 12.5 μg/kg, 12% (95% CI, 7-22) after 25 μg/kg, 31% (95% CI, 22-42) after 50 μg/kg, 72% (95% CI, 61-81) after 100 μg/kg, and 96% (95% CI, 89-99) after 200 μg/ kg (or the maximum doses for ≥60 kg; Figure 3 ). The median longest RR interval at the time of atrioventricular block was 1.9 seconds (interquartile range, 1.4-3.2 seconds), and the mean total adenosine effect was 4.3±2.0 seconds, with both the longest RR interval and total adenosine effect lasting 8.4 seconds. The median number of blocked P waves during the longest pause was 2 (interquartile range, 1-3). Although the majority of patients without general anesthesia for testing reported symptoms with adenosine, no patient terminated testing because of adverse symptoms ( Table 2) . QRS interval >100 ms, n (%) 21 (26) Native P wave present, n (%) 9 (11) Native P wave present with biatrial anastomosis (n=22), n (%) 4 (18) General anesthesia, n (%) 51 (64)
Cardiac index, L·min In univariable analyses, the baseline PR interval on ECG was the only statistically significant predictor of the adenosine dose required to achieve atrioventricular block (P=0.034); for every 10-millisecond increase in baseline PR, the adenosine dose required for atrioventricular block decreased by 0.01 μg (Tables I and II in the  online-only Data Supplement) . No variable significantly predicted total adenosine effect. These results did not change when stratified by weight (>60 or <60 kg). It is notable that there was no significant association between time from transplantation and maximum adenosine dose; of the 20 patients <2 years from transplantation, 1 (55%) required adenosine doses ≥100 μg/kg.
DISCUSSION
The safety and efficacy of adenosine use in pediatric and young adult heart transplantation patients were critically assessed through this prospective study. Study results demonstrated that adenosine at 25 μg/kg was safe; no patient experienced clinically significant asystole at this dose. For doses >25 μg/kg, an escalating dose strategy was a safe approach; freedom from ventricular pacing remained 100% throughout the study. Last, the study confirmed that adenosine could be effective at lower doses than are typically used in patients without cardiac transplantation.
Diagnostic and therapeutic options for pediatric heart transplantation patients with SVT have been traditionally limited to intravenous verapamil, other antiarrhythmic medications, or cardioversion. However, such alternatives can have a longer half-life or onset of action and carry significant adverse risk profiles. [17] [18] [19] Verapamil in particular is contraindicated in infants <1 year of age and can impair the metabolism of 2 common immunosuppression medications (tacrolimus and cyclosporine). [20] [21] [22] Synchronized electric cardioversion requires procedural sedation, which Values are mean±SD; IQR denotes an IQR after a median result. IQR indicates interquartile range.
*Atrioventricular block duration was measured as the single longest R-R interval on the ECG. †Patients reporting symptoms were not under general anesthesia.
can potentially be higher risk in the setting of cardiac dysfunction, coronary allograft vasculopathy, and acute rejection, of which the arrhythmia may be the sentinel event. 23, 24 For more than a quarter-century, adenosine has been considered relatively contraindicated in heart transplantation patients with SVT because of the presumed risk of prolonged atrioventricular block. In 1990, Ellenbogen et al 10 hypothesized that denervated sinus and atrioventricular nodes would have a greater response to adenosine because of its parallel and synergistic effects with acetylcholine. Their group demonstrated that the duration of sinus and atrioventricular node slowing in response to adenosine was 3-to 5-fold greater in an adult heart transplantation cohort than controls, suggesting that a lower starting dose could be effective. In 1993, after a report of a 19-year-old transplantation patient requiring resuscitation as a result of severe sinus bradycardia and atrioventricular block after standard adult dosing, those authors recommended that adenosine be used with caution in the transplantation population. 13 In comparison, the current adenosine study confirmed that doses as low as 25 μg/kg for children, which is one quarter the recommended pediatric advanced life support starting dose of 100 μg/kg, and 1.5 mg for young adults (≥60 kg), which is one quarter the recommended adult advanced cardiovascular life support starting dose of 6 mg, are safe in transplantation patients and can also be effective. 25, 26 Similarly, presuming that the 19-year-old patient was of adult weight (≥60 kg), the 6-mg dose would have been 4 times greater than the 1.5-mg dose at which this study first observed atrioventricular block.
This study examines the historical premise that denervated hearts are supersensitive to adenosine, challenging the long-standing reservation that adenosine use is universally dangerous in this population. Although all transplanted hearts are surgically denervated at the time of operation and posttransplantation reinnervation is an accepted phenomenon, the timing of reinnervation is not well understood. Estimates of the timing of sympathetic reinnervation have varied, with some evidence as early as 2 to 4 years after transplantation. [27] [28] [29] Overall, this study did not reveal any relationship between effective adenosine dose and time from transplantation and suggests that adenosine can be safe as early as posttransplantation day 25. Therefore, when considering adenosine dosing, cardiac denervation may be less important than the general metabolism of adenosine or individual dose-response variability, or indicate that time from transplantation does not serve as an accurate surrogate marker for reinnervation; however, this study was not designed to detect that specific difference.
There are several notable limitations to this study. Adenosine was tested in healthy transplantation patients in normal hemodynamic settings. Although it might be assumed that results would be similar in acutely ill, tachycardic patients, this has yet to be demonstrated. Heart rate and rejection may affect the cardiac index, changing the time required to circulate the adenosine and its overall metabolism, with both factors likely resulting in the study underestimating the amount of adenosine that is efficacious. Furthermore, patients with acute onset of tachycardia are less likely to have central access (as this cohort did) and more likely to receive only peripheral intravenous lines. Because of the very short half-life of adenosine, larger doses may be required when injected through smaller and more distant peripheral veins, consistent with findings in an early comparison study. 30 Conversely, the resumption of sinus rhythm in a tachycardic patient might take longer than it did in the study patients because of overdrive suppression of the sinus node. 31 Therefore, the length of sinus pauses and total adenosine effect may have been underestimated.
Approximately two thirds of patients were under general anesthesia during adenosine testing, which would be unlikely for patients presenting with a new tachyarrhythmia. However, no difference was noted in total adenosine effect between anesthetized and nonanesthetized patients. In addition, >95% of patients had normal biopsies; thus, the study is unable to comment on the safety and efficacy of adenosine in the setting of rejection. Also of note, the majority of the patients were tested >2 years after transplantation, therefore limiting the ability to compare adenosine dosing within an earlier postoperative time. Last, this study did not test patients on dipyridamole therapy, which has been previously described to decrease adenosine metabolism. Dosing recommendations may need to be altered for patients maintained on this or other medications that might affect adenosine metabolism, which is an important area of future investigation.
CONCLUSION
This is the first study to demonstrate that adenosine is both safe and efficacious in pediatric and young adult heart transplantation patients. In the evaluation and treatment of SVT after transplantation, this study suggests that adenosine can be safely used as a first-line medication, starting at much lower doses (25 μg/kg; 1.5 mg for patients ≥60 kg) than suggested by current pediatric advanced life support and adult advanced cardiovascular life support guidelines, and then therapy can gradually be escalated to achieve atrioventricular block. Future clinical studies to investigate adenosine dosing in the setting of tachycardia and with other common transplantation medications are warranted.
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